Association between leptin and transaminases: 1-year follow-up study in 180 overweight children

Thomas Reinehr1, Caroline Schmidt, Gideon de Sousa

  • 1Vestische Hospital for Children and Adolescents, University of Witten-Herdecke, 45711 Datteln, Germany. t.reinehr@kinderklinik-datteln.de

Insights

Leptin levels, not insulin resistance, correlated with elevated liver enzymes in overweight children. Weight loss improved transaminases, suggesting leptin

Area of Science:

  • Pediatric Endocrinology
  • Hepatology
  • Metabolic Syndrome

Background:

  • Nonalcoholic fatty liver disease (NAFLD) is linked to leptin and insulin resistance.
  • Elevated transaminases (AST, ALT) are common in NAFLD.
  • Longitudinal data on leptin, insulin resistance, and transaminases in children are limited.

Purpose of the Study:

  • To investigate the longitudinal association between leptin, insulin resistance, and liver transaminases in overweight children.
  • To assess the impact of lifestyle intervention on these parameters.

Main Methods:

  • 180 overweight children were studied at baseline and 1 year later.
  • Measurements included weight status (BMI SDS), AST, ALT, leptin, glucose, and insulin.
  • Multiple regression analysis was used, adjusting for age, sex, pubertal stage, and BMI SDS.

Main Results:

  • Leptin, but not insulin resistance (HOMA-IR), showed significant cross-sectional and longitudinal correlations with transaminases.
  • Children in a lifestyle intervention group who lost weight (>0.5 BMI SDS) showed reduced ALT and AST levels.
  • Children without weight loss or intervention showed increased transaminase levels.

Conclusions:

  • Leptin may play a role in the pathogenesis of pediatric liver disease.
  • Weight reduction is associated with improved liver enzyme levels in overweight children.
  • Further studies with histological assessment are needed to confirm leptin's role.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...